These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 20478341)
1. Downstream effects of haemoglobinase inhibition in Plasmodium falciparum-infected erythrocytes. Naughton JA; Nasizadeh S; Bell A Mol Biochem Parasitol; 2010 Oct; 173(2):81-7. PubMed ID: 20478341 [TBL] [Abstract][Full Text] [Related]
2. Excess haemoglobin digestion by malaria parasites: a strategy to prevent premature host cell lysis. Lew VL; Macdonald L; Ginsburg H; Krugliak M; Tiffert T Blood Cells Mol Dis; 2004; 32(3):353-9. PubMed ID: 15121091 [TBL] [Abstract][Full Text] [Related]
3. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development. Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329 [TBL] [Abstract][Full Text] [Related]
4. Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets. Qidwai T Curr Drug Targets; 2015; 16(10):1133-41. PubMed ID: 25738296 [TBL] [Abstract][Full Text] [Related]
5. Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II. Jin H; Xu Z; Cui K; Zhang T; Lu W; Huang J Fitoterapia; 2014 Apr; 94():55-61. PubMed ID: 24468190 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease. Domínguez JN; López S; Charris J; Iarruso L; Lobo G; Semenov A; Olson JE; Rosenthal PJ J Med Chem; 1997 Aug; 40(17):2726-32. PubMed ID: 9276017 [TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Plasmepsin II-potential antimalarial agents. Corminboeuf O; Dunet G; Hafsi M; Grimont J; Grisostomi C; Meyer S; Binkert C; Bur D; Jones A; Prade L; Brun R; Boss C Bioorg Med Chem Lett; 2006 Dec; 16(24):6194-9. PubMed ID: 17000102 [TBL] [Abstract][Full Text] [Related]
9. Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function. Bonilla JA; Bonilla TD; Yowell CA; Fujioka H; Dame JB Mol Microbiol; 2007 Jul; 65(1):64-75. PubMed ID: 17581121 [TBL] [Abstract][Full Text] [Related]
10. The role of aminopeptidases in haemoglobin degradation in Plasmodium falciparum-infected erythrocytes. Gavigan CS; Dalton JP; Bell A Mol Biochem Parasitol; 2001 Sep; 117(1):37-48. PubMed ID: 11551630 [TBL] [Abstract][Full Text] [Related]
11. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum. Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719 [TBL] [Abstract][Full Text] [Related]
13. Generation of an affinity matrix useful in the purification of natural inhibitors of plasmepsin II, an antimalarial-drug target. Ramírez AR; Guerra Y; Otero A; García B; Berry C; Mendiola J; Hernández-Zanui A; Chávez Mde L Biotechnol Appl Biochem; 2009 Feb; 52(Pt 2):149-57. PubMed ID: 18471091 [TBL] [Abstract][Full Text] [Related]
14. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D. Dali B; Keita M; Megnassan E; Frecer V; Miertus S Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes. Nöteberg D; Hamelink E; Hultén J; Wahlgren M; Vrang L; Samuelsson B; Hallberg A J Med Chem; 2003 Feb; 46(5):734-46. PubMed ID: 12593654 [TBL] [Abstract][Full Text] [Related]
16. Studies on plasmepsins I and II from the malarial parasite Plasmodium falciparum and their exploitation as drug targets. Moon RP; Bur D; Loetscher H; D'Arcy A; Tyas L; Oefner C; Grueninger-Leitch F; Mona D; Rupp K; Dorn A; Matile H; Certa U; Berry C; Kay J; Ridley RG Adv Exp Med Biol; 1998; 436():397-406. PubMed ID: 9561248 [No Abstract] [Full Text] [Related]
17. Susceptibility of Plasmodium falciparum to glutamate dehydrogenase inhibitors--a possible new antimalarial target. Aparicio IM; Marín-Menéndez A; Bell A; Engel PC Mol Biochem Parasitol; 2010 Aug; 172(2):152-5. PubMed ID: 20399810 [TBL] [Abstract][Full Text] [Related]
18. Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. Coterón JM; Catterick D; Castro J; Chaparro MJ; Díaz B; Fernández E; Ferrer S; Gamo FJ; Gordo M; Gut J; de las Heras L; Legac J; Marco M; Miguel J; Muñoz V; Porras E; de la Rosa JC; Ruiz JR; Sandoval E; Ventosa P; Rosenthal PJ; Fiandor JM J Med Chem; 2010 Aug; 53(16):6129-52. PubMed ID: 20672841 [TBL] [Abstract][Full Text] [Related]
19. Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Sijwali PS; Shenai BR; Gut J; Singh A; Rosenthal PJ Biochem J; 2001 Dec; 360(Pt 2):481-9. PubMed ID: 11716777 [TBL] [Abstract][Full Text] [Related]
20. Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. Sijwali PS; Koo J; Singh N; Rosenthal PJ Mol Biochem Parasitol; 2006 Nov; 150(1):96-106. PubMed ID: 16890302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]